Recent share performance and business profile

Charles River Laboratories International (CRL) has drawn investor attention after recent share price moves, with the stock up about 5% over the past month and roughly 11% over the past 3 months.

The company provides drug discovery, non clinical development, and safety testing services. It generates about US$4.0b in revenue and operates across the United States, Europe, Canada, and the Asia Pacific region.

Recent trading has been firm, with a 2.81% 1 day share price return and an 11.39% 90 day share price return. This contrasts with a year to date share price decline of 7.89% and a mixed longer term total shareholder return record.

If you are comparing Charles River’s setup with other opportunities in the sector, it may be worth scanning companies exposed to healthcare related artificial intelligence through the 39 healthcare AI stocks.

With CRL shares recovering over the past quarter but still down year to date, the key question is whether recent earnings trends and analyst optimism leave the stock undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 40.6% Undervalued

The current Charles River share price of $186.44 sits well below the $313.61 fair value implied by the most followed narrative, which frames the recent move as only part of the story.

The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier

On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M]

At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry.

However, the deeper implication is far more significant.

The deal effectively expands and secures access to NHP supply, highlighting how critical primate availability has become in modern drug development.

In other words, this acquisition reveals one of the hidden bottlenecks in the pharmaceutical research ecosystem: the supply of non-human primates.

Want to see why a 40% plus gap to fair value still makes sense in this narrative? The core assumptions lean on revenue expansion, higher profit margins, and a future earnings multiple that reflects a stronger, more profitable contract research platform.

Result: Fair Value of $313.61 (UNDERVALUED)

However, this upbeat setup still faces risks, including regulatory pressure around non human primate use and the fact that Charles River currently reports a net loss of US$184.65m.

Another View: Cash Flows Paint a Tougher Picture

That community narrative points to a $313.61 fair value, but the SWS DCF model tells a very different story. On that cash flow view, CRL at $186.44 is trading well above an estimated $78.47 value. This suggests the current price may already reflect a significant amount of optimism. Which lens do you trust more when the signals clash like this?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such mixed signals on value and sentiment, the real edge comes from testing the assumptions yourself and acting before the next narrative shift, starting by weighing 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If CRL has you thinking more carefully about price and risk, do not stop here. The best opportunities often sit just beyond the obvious tickers.

• Target reliable cash generators by scanning the solid balance sheet and fundamentals stocks screener (46 results) and focus on companies with room to handle shocks without stressing their finances.
• Hunt for potential mispricings using the 47 high quality undervalued stocks so you are not leaving possible value opportunities on the table while others act first.
• Prioritise resilience with the 63 resilient stocks with low risk scores and concentrate your research on businesses that score well on financial strength and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.